Cargando…
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
AIM: This study aimed to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ), to prevent disease progression, subcutaneously administered to patients with moderate COVID-19 pneumonia and hyperinflammation. METHODS: Clinical characteristics and outcomes were retrospectively analyse...
Autores principales: | Potere, Nicola, Di Nisio, Marcello, Rizzo, Giulia, La Vella, Matteo, Polilli, Ennio, Agostinone, Adriana, Spacone, Antonella, Di Carlo, Silvio, Costantini, Alberto, Abbate, Antonio, Porreca, Ettore, Parruti, Giustino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406468/ https://www.ncbi.nlm.nih.gov/pubmed/32768701 http://dx.doi.org/10.1016/j.ijid.2020.07.078 |
Ejemplares similares
-
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
por: Di Nisio, Marcello, et al.
Publicado: (2021) -
Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism
por: Potere, Nicola, et al.
Publicado: (2023) -
Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis
por: Potere, Nicola, et al.
Publicado: (2020) -
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone
por: Potere, Nicola, et al.
Publicado: (2021) -
Analysis of peripheral blood lymphocyte subsets in critical patients
at ICU admission: A preliminary investigation of their role in the prediction of
sepsis during ICU stay
por: Frattari, Antonella, et al.
Publicado: (2018)